CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 2. Electroporation of a synthetic Grb2-SH2 blocking peptide or compound 8 inhibits Grb2 binding to growth factor receptors. The Grb2-SH2 binding peptide containing Pmp at the position of phosphotyrosine (Lanes 2 and 5), a control phenylalanine-containing peptide (Lanes 3 and 6), or compound 8 (Lane 7) was electroporated into mouse NIH-3T3 fibroblasts (Lanes 1–3), human lung carcinoma A549 cells (Lanes 4–6), or NIH-3T3-methu cells (Lanes 7–9). Cells were subsequently stimulated with PDGF (Lanes 2 and 3), HGF (Lanes 5 and 6), or EGF (Lanes 8 and 9), as indicated. Lanes 1, 4, and 8, unstimulated controls. Detergent cell extracts were precipitated with a Grb2-specific antibody, and proteins were resolved by PAGE and transferred to a nitrocellulose membrane probed with antibodies to phosphotyrosine (Lanes 1–3), Met (Lanes 4–6), or EGFR (Lanes 7–9). Horizontal bar, the position of the Mr 116,000 marker.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation